Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia

Assessment report (PDF 886 KB)

Insomnia - newer hypnotic drugs: review decision - August 2010 information

Appendix A: Decision paper considered by the Institute's Guidance Executive (PDF 72 KB)

Review Proposal - May 2010 information

Appendix A: Provisional matrix of consultees and commentators (MSWord 69 KB)

Appendix B: Proposal paper presented to NICE's Guidance Executive (PDF 109 KB)

TA77 Insomnia - newer hypnotic drugs: distribution list (PDF 56 KB)

Review proposal - September 2007 information

Review decision - November 2007 information

Appendix 1

Actavis (PDF 15 KB)

British Sleep Society (PDF 9 KB)

Counsel and Care (PDF 9.4 KB)

Department of Health (PDF 8.5 KB)

Dowelhurst Ltd (PDF 9.9 KB)

NHS Quality Improvement Scotland (PDF 9.7 KB)

Pfizer Ltd (PDF 9.3 KB)

Royal College of Nursing (PDF 9.7 KB)

Rosemont Pharmaceuticals (PDF 9.1 KB)

Sandoz Ltd (PDF 8.6 KB)

Teva UK (PDF 8.6 KB)

Wyeth Pharmaceuticals (PDF 9.4 KB)

Appendix A - Matrix of consultees and commentators. (PDF 59 KB)

Final Appraisal Determination: Zaleplon, zolpidem and zopiclone for the short-term management of insomnia (PDF 162 KB)

Appraisal Consultation Document: Zaleplon, zolpidem and zopiclone for the management of insomnia information

Protocol: Newer hypnotic drugs for short-term pharmacotherapy for insomnia (PDF 201 KB)

Final Scope: Zaleplon, zolpidem and zopiclone for the management of short-term insomnia (PDF 70 KB)